Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01974440




Registration number
NCT01974440
Ethics application status
Date submitted
28/10/2013
Date registered
1/11/2013
Date last updated
9/08/2024

Titles & IDs
Public title
A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma
Scientific title
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL)
Secondary ID [1] 0 0
PCI-32765FLR3001
Secondary ID [2] 0 0
CR102786
Universal Trial Number (UTN)
Trial acronym
SELENE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Bendamustine
Treatment: Drugs - Rituximab
Treatment: Drugs - Cyclophosphamide
Treatment: Drugs - Doxorubicin
Treatment: Drugs - Vincristine
Treatment: Drugs - Prednisone
Treatment: Drugs - PCI-32765 (Ibrutinib)
Treatment: Drugs - Placebo

Placebo comparator: Treatment Arm A - Treatment Arm A = background immune-chemotherapy (bendamustine and rituximab \[BR\] or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone \[R-CHOP\]) for 6 cycles + placebo.

Experimental: Treatment Arm B - Treatment Arm B = background immune-chemotherapy (BR or R-CHOP) for 6 cycles + PCI-32765 (Ibrutinib).


Treatment: Drugs: Bendamustine
90 milligram per meter square (mg/m\^2) administered intravenously on Days 1 to 2 of Cycles 1 to 6.

Treatment: Drugs: Rituximab
375 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.

Treatment: Drugs: Cyclophosphamide
750 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.

Treatment: Drugs: Doxorubicin
50 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.

Treatment: Drugs: Vincristine
1.4 mg/m\^2 (maximum total 2 mg) administered intravenously on Day 1 of Cycles 1 to 6.

Treatment: Drugs: Prednisone
100 mg administered orally on Days 1 to 5 of Cycles 1 to 6.

Treatment: Drugs: PCI-32765 (Ibrutinib)
560 mg (4\*140 mg) capsules administered orally once daily, continuously starting on Cycle 1, Day 1.

Treatment: Drugs: Placebo
Placebo (4 capsules) matched to ibrutinib administered orally once daily, continuously starting on Cycle 1, Day 1.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Primary Analysis: Progression Free Survival (PFS): Stratified Analysis
Timepoint [1] 0 0
Up to 8 years
Primary outcome [2] 0 0
Supplementary Analysis: Progression Free Survival: Unstratified Analysis - Participants With Marginal Zone Lymphoma (MZL)
Timepoint [2] 0 0
Up to 8 years
Secondary outcome [1] 0 0
Primary Analysis: Overall Survival (OS): Stratified Analysis
Timepoint [1] 0 0
Up to 8 years
Secondary outcome [2] 0 0
Supplementary Analysis: Overall Survival: Unstratified Analysis - Participants With MZL
Timepoint [2] 0 0
Up to 8 years
Secondary outcome [3] 0 0
Primary Analysis: Complete Response Rate (CRR): Stratified Analysis
Timepoint [3] 0 0
Up to 8 years
Secondary outcome [4] 0 0
Supplementary Analysis: Complete Response Rate: Unstratified Analysis - Participants With MZL
Timepoint [4] 0 0
Up to 8 years
Secondary outcome [5] 0 0
Primary Analysis: Overall Response Rate (ORR): Stratified Analysis
Timepoint [5] 0 0
Up to 8 years
Secondary outcome [6] 0 0
Supplementary Analysis: Overall Response Rate: Unstratified Analysis - Participants With MZL
Timepoint [6] 0 0
Up to 8 years
Secondary outcome [7] 0 0
Primary Analysis: Duration of Response (DOR): Stratified Analysis
Timepoint [7] 0 0
Up to 8 years
Secondary outcome [8] 0 0
Supplementary Analysis: Duration of Response: Unstratified Analysis - Participants With MZL
Timepoint [8] 0 0
Up to 8 years
Secondary outcome [9] 0 0
Primary Analysis: Time to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy - Lymphoma Subscale (FACT-LymS) Questionnaire
Timepoint [9] 0 0
Up to 8 years
Secondary outcome [10] 0 0
Supplementary Analysis: Time to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy - Lymphoma Subscale (FACT-LymS) Questionnaire: Participants With MZL
Timepoint [10] 0 0
Up to 8 years
Secondary outcome [11] 0 0
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Timepoint [11] 0 0
Placebo + Chemoimmunotherapy (CIT) arm: From Day 1 up to 30 days after date of last dose of study medication (up to 8 years); Ibrutinib + CIT arm: From Day 1 up to 30 days after date of last dose of study medication (up to 8 years 8 months)
Secondary outcome [12] 0 0
Number of Participants With TEAEs: Participants With MZL
Timepoint [12] 0 0
Placebo + Chemoimmunotherapy (CIT) arm: From Day 1 up to 30 days after date of last dose of study medication (up to 8 years); Ibrutinib + CIT arm: From Day 1 up to 30 days after date of last dose of study medication (up to 8 years 8 months)

Eligibility
Key inclusion criteria
* Histologically confirmed diagnosis of B-cell indolent Non-Hodgkin lymphoma with histological subtype limited to follicular lymphoma or marginal zone lymphoma, at initial diagnosis and without evidence of pathological transformation or clinical signs suggesting transformation
* At least 1 prior treatment with a CD20 antibody combination chemo-immunotherapy regimen
* Disease that has relapsed or was refractory after prior chemo-immunotherapy
* At least 1 measurable site of disease according to Revised Response Criteria for Malignant Lymphoma 2007
* Eastern Cooperative Oncology Group performance status grade 0 or 1
* Laboratory values within protocol-defined parameters
* Agrees to protocol-defined use of effective contraception
* Men must agree not to donate sperm during and after the study for 6 months after the last dose of bendamustine, 12 months after the last dose of rituximab, or 3 months after the last dose of study medication, whichever is later
* Women of childbearing potential must have a negative serum or urine pregnancy test at Screening
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Prior treatment according to protocol-defined criteria
* Unable to receive background chemotherapy based on prior treatment history and cardiac function
* Known central nervous system lymphoma
* Diagnosed or treated for malignancy other than indolent Non-Hodgkin lymphoma
* History of stroke or intracranial hemorrhage within 6 months prior to randomization
* Requires anticoagulation with warfarin or equivalent Vitamin K antagonists
* Requires treatment with strong CYP3A inhibitors
* Clinically significant cardiovascular disease
* Known history of human immunodeficiency virus or active hepatitis C virus (HCV; ribonucleic acid [RNA] polymerase chain reaction [PCR]-positive) or active hepatitis B virus (HBV; DNA PCR-positive) infection or any uncontrolled active systemic infection requiring intravenous antibiotics
* Any life-threatening illness, medical condition, or organ system dysfunction which, in the Investigator's opinion, could compromise the participant's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
* Women who are pregnant or breastfeeding

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
31/01/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
21/06/2023
Sample size
Target
Accrual to date
Final
403
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Adelaide
Recruitment hospital [2] 0 0
- Fitzroy
Recruitment hospital [3] 0 0
- Heidelberg
Recruitment hospital [4] 0 0
- South Brisbane
Recruitment hospital [5] 0 0
- Wahroonga
Recruitment hospital [6] 0 0
- Westmead
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Fitzroy
Recruitment postcode(s) [3] 0 0
- Heidelberg
Recruitment postcode(s) [4] 0 0
- South Brisbane
Recruitment postcode(s) [5] 0 0
- Wahroonga
Recruitment postcode(s) [6] 0 0
- Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Indiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Kansas
Country [7] 0 0
United States of America
State/province [7] 0 0
Kentucky
Country [8] 0 0
United States of America
State/province [8] 0 0
Louisiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Maine
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Minnesota
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Oregon
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
South Dakota
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Washington
Country [22] 0 0
United States of America
State/province [22] 0 0
Wisconsin
Country [23] 0 0
Argentina
State/province [23] 0 0
Buenos Aires
Country [24] 0 0
Argentina
State/province [24] 0 0
Ciudad Autonoma Buenos Aires
Country [25] 0 0
Argentina
State/province [25] 0 0
Cordoba
Country [26] 0 0
Argentina
State/province [26] 0 0
La Capital
Country [27] 0 0
Argentina
State/province [27] 0 0
Mendoza
Country [28] 0 0
Argentina
State/province [28] 0 0
Santa Fe
Country [29] 0 0
Belgium
State/province [29] 0 0
Anderlecht
Country [30] 0 0
Belgium
State/province [30] 0 0
Edegem
Country [31] 0 0
Belgium
State/province [31] 0 0
Gent
Country [32] 0 0
Belgium
State/province [32] 0 0
Leuven
Country [33] 0 0
Belgium
State/province [33] 0 0
Namur
Country [34] 0 0
Belgium
State/province [34] 0 0
Wilrijk
Country [35] 0 0
Brazil
State/province [35] 0 0
Porto Alegre
Country [36] 0 0
Brazil
State/province [36] 0 0
Rio De Janeiro
Country [37] 0 0
Brazil
State/province [37] 0 0
Salvador
Country [38] 0 0
Brazil
State/province [38] 0 0
Sao Paulo
Country [39] 0 0
Brazil
State/province [39] 0 0
São Paulo
Country [40] 0 0
China
State/province [40] 0 0
Beijing
Country [41] 0 0
China
State/province [41] 0 0
Chengdu
Country [42] 0 0
China
State/province [42] 0 0
Guangzhou
Country [43] 0 0
China
State/province [43] 0 0
Hangzhou
Country [44] 0 0
China
State/province [44] 0 0
Harbin
Country [45] 0 0
China
State/province [45] 0 0
Nanjing
Country [46] 0 0
China
State/province [46] 0 0
Shanghai
Country [47] 0 0
China
State/province [47] 0 0
Tianjin
Country [48] 0 0
France
State/province [48] 0 0
Nice Cedex 2
Country [49] 0 0
France
State/province [49] 0 0
Paris
Country [50] 0 0
France
State/province [50] 0 0
Pessac
Country [51] 0 0
France
State/province [51] 0 0
Pierre Benite
Country [52] 0 0
France
State/province [52] 0 0
Rennes
Country [53] 0 0
Germany
State/province [53] 0 0
Berlin
Country [54] 0 0
Germany
State/province [54] 0 0
Gießen
Country [55] 0 0
Germany
State/province [55] 0 0
Göttingen
Country [56] 0 0
Germany
State/province [56] 0 0
Ludwigshafen, Rp
Country [57] 0 0
Germany
State/province [57] 0 0
Magdeburg
Country [58] 0 0
Germany
State/province [58] 0 0
Mainz
Country [59] 0 0
Germany
State/province [59] 0 0
Munchen
Country [60] 0 0
Germany
State/province [60] 0 0
Wiesbaden
Country [61] 0 0
Israel
State/province [61] 0 0
Hadera
Country [62] 0 0
Israel
State/province [62] 0 0
Haifa
Country [63] 0 0
Israel
State/province [63] 0 0
Jerusalem
Country [64] 0 0
Israel
State/province [64] 0 0
Nahariya
Country [65] 0 0
Israel
State/province [65] 0 0
Netanya
Country [66] 0 0
Israel
State/province [66] 0 0
Petah Tikva
Country [67] 0 0
Israel
State/province [67] 0 0
Ramat Gan
Country [68] 0 0
Japan
State/province [68] 0 0
Chuo Ku
Country [69] 0 0
Japan
State/province [69] 0 0
Hiroshima shi
Country [70] 0 0
Japan
State/province [70] 0 0
Isehara
Country [71] 0 0
Japan
State/province [71] 0 0
Kobe
Country [72] 0 0
Japan
State/province [72] 0 0
Nagoya-shi
Country [73] 0 0
Japan
State/province [73] 0 0
Osaka Sayama shi
Country [74] 0 0
Japan
State/province [74] 0 0
Sapporo-shi
Country [75] 0 0
Japan
State/province [75] 0 0
Sendai shi
Country [76] 0 0
Japan
State/province [76] 0 0
Suita-shi
Country [77] 0 0
Japan
State/province [77] 0 0
Tokyo
Country [78] 0 0
Korea, Republic of
State/province [78] 0 0
Jeollanam-do
Country [79] 0 0
Korea, Republic of
State/province [79] 0 0
Seoul
Country [80] 0 0
Poland
State/province [80] 0 0
Gdynia
Country [81] 0 0
Poland
State/province [81] 0 0
Olsztyn
Country [82] 0 0
Poland
State/province [82] 0 0
Warszawa
Country [83] 0 0
Puerto Rico
State/province [83] 0 0
Bayamon
Country [84] 0 0
Puerto Rico
State/province [84] 0 0
Ponce
Country [85] 0 0
Puerto Rico
State/province [85] 0 0
San Juan
Country [86] 0 0
Russian Federation
State/province [86] 0 0
Krasnodar
Country [87] 0 0
Russian Federation
State/province [87] 0 0
Moscow
Country [88] 0 0
Russian Federation
State/province [88] 0 0
Nizny Novgorod
Country [89] 0 0
Russian Federation
State/province [89] 0 0
Petrozavodsk
Country [90] 0 0
Russian Federation
State/province [90] 0 0
Pyatigorsk
Country [91] 0 0
Russian Federation
State/province [91] 0 0
Rostov-On-Don
Country [92] 0 0
Russian Federation
State/province [92] 0 0
St. Petersburg
Country [93] 0 0
Russian Federation
State/province [93] 0 0
Syktyvkar
Country [94] 0 0
Russian Federation
State/province [94] 0 0
Volgograd
Country [95] 0 0
Spain
State/province [95] 0 0
Barcelona
Country [96] 0 0
Spain
State/province [96] 0 0
Madrid
Country [97] 0 0
Spain
State/province [97] 0 0
Pozuelo de Alarcon
Country [98] 0 0
Spain
State/province [98] 0 0
Salamanca
Country [99] 0 0
Sweden
State/province [99] 0 0
Göteborg
Country [100] 0 0
Sweden
State/province [100] 0 0
Linköping
Country [101] 0 0
Sweden
State/province [101] 0 0
Luleå
Country [102] 0 0
Sweden
State/province [102] 0 0
Uppsala
Country [103] 0 0
Turkey
State/province [103] 0 0
Ankara
Country [104] 0 0
Turkey
State/province [104] 0 0
Antalya
Country [105] 0 0
Turkey
State/province [105] 0 0
Istanbul
Country [106] 0 0
Turkey
State/province [106] 0 0
Izmir
Country [107] 0 0
Turkey
State/province [107] 0 0
Kayseri
Country [108] 0 0
Ukraine
State/province [108] 0 0
Cherkasy
Country [109] 0 0
Ukraine
State/province [109] 0 0
Ivano-Frankivsk
Country [110] 0 0
Ukraine
State/province [110] 0 0
Khmelnitskiy
Country [111] 0 0
Ukraine
State/province [111] 0 0
Kiev
Country [112] 0 0
Ukraine
State/province [112] 0 0
Lviv
Country [113] 0 0
Ukraine
State/province [113] 0 0
Uzhgorod
Country [114] 0 0
United Kingdom
State/province [114] 0 0
Glasgow
Country [115] 0 0
United Kingdom
State/province [115] 0 0
London
Country [116] 0 0
United Kingdom
State/province [116] 0 0
Newcastle upon Tyne
Country [117] 0 0
United Kingdom
State/province [117] 0 0
Plymouth
Country [118] 0 0
United Kingdom
State/province [118] 0 0
Portsmouth
Country [119] 0 0
United Kingdom
State/province [119] 0 0
Sutton
Country [120] 0 0
United Kingdom
State/province [120] 0 0
Swansea

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Janssen Research & Development, LLC
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Pharmacyclics LLC.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT01974440